Xalles Subsidiary Launches New Technology Services

Rhea-AI Summary

Xalles Holdings Inc. (OTC: XALL) has launched Argus-Rx, a health and prescription ecommerce platform, enabling discounts of up to 80% on prescription prices. This initiative aims to enhance revenue for Xalles and its partners. Additionally, Xalles has introduced new Data Asset Management services. The company is also working on completing prior acquisitions, including Adaptive and 1Rivet Global, after delays in payments related to the MinervaWorks acquisition.

Positive

• Launch of Argus-Rx platform could increase revenue significantly.
• Argus-Rx provides discounts of up to 80% on prescriptions, appealing to consumers.
• Introduction of new Data Asset Management services to assist corporate clients.

Negative

• Delays in completing acquisition payments for MinervaWorks.
• Ongoing challenges with finalizing other acquisitions, potentially impacting growth.

Argus Technology Partners is Now Offering Argus-RX Through Their Ecommerce Platform and New Technology Management Services

WASHINGTON, DC, March 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing technology and financial services solutions, announces subsidiary updates including the addition of new service offerings and revenue sources.

Argus Technology Partners, a wholly owned subsidiary of Xalles Technology, has launched Argus-Rx. It is a one-stop health and prescriptions ecommerce site. It includes an easy-to-use search engine for prescription discounts and health products to enable customers to receive up to 80% off the cash price of prescriptions. The www.Argus-Rx.com site will generate revenue for Argus and Argus Technology’s corporate clients and strategic partners.

This Argus ecommerce platform is strategic for Xalles since it will be enhanced with new payment technology that will enable the company to quickly capture large numbers of new users into a mobile payment wallet for growing revenue in multiple projects. As the market is changing regarding healthcare and employer role responsibilities, this pharmacy savings platform is a strategic entrance into a new healthcare and payments ecosystem.

Argus Technology Partners is also pleased to announce its new Data Asset Management and Forensic Technology Auditing services. Argus leverages state-of-the-art platforms to assist clients to fully assess every asset and application on an entire corporate technology environment. Argus aims to help organizations regain control of their networks.

Xalles is also providing an update about the previously announced MinervaWorks acquisition. After the closing events of March 31, 2020, the remainder of the acquisition, including buyout payments to MinervaWorks’ original shareholders, was not completed and the filings will be updated accordingly.

Xalles continues to work with the management teams to complete the closing events for the previously announced acquisitions of Adaptive, 1Rivet Global, Crown Solutions and Protominds.

About Xalles Holdings Inc. (OTC: XALL)

Xalles Holdings Inc. is a holding company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets in which it can invest and accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams. For more information visit: http://Xalles.com

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov and in OTC Markets at www.otcmarkets.com.

Investor Relations Contact:
info@xalles.com
www.xalles.com
202.595.1299 Office 

FAQ

What is Argus-Rx and how does it benefit consumers?

Argus-Rx is an ecommerce platform launched by Xalles Holdings that offers discounts on prescriptions, enabling customers to save up to 80%.

How does Xalles plan to generate revenue through Argus-Rx?

The Argus-Rx platform aims to generate revenue for Xalles by partnering with corporate clients and strategic partners.

What new services has Xalles introduced recently?

Xalles has introduced Data Asset Management and Forensic Technology Auditing services to help clients manage their technology assets.

What challenges is Xalles facing regarding its acquisitions?

Xalles is encountering delays in completing buyout payments for MinervaWorks and other acquisitions.

What is the stock symbol for Xalles Holdings?

The stock symbol for Xalles Holdings is XALL.